NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

no recurrence for more than 10 years now

RK, I was blown away by this part of your post

Dr. Liau and her colleagues developed the first dendritic cell (DC)-based vaccine, known as DCVax, for brain-tumor patients to be used in humans. "The problem with brain tumors is that, despite treatment, they tend to come back," Dr. Liau says. "The promise of immunotherapy and vaccines is that they can hopefully prevent the cancer from returning."
Fifteen years ago, most experts believed it was not possible, because of the blood-brain barrier, for patients to mount an immune response to brain cancers. "We’ve found that these tumor vaccines can not only mount an immune response, but that a significant percentage of patients have had no recurrence for more than 10 years now, which for glioblastoma is very rare," Dr. Liau says.

This is from one of the worlds most renowned Professors of Neurology - Dr Linda Liau of UCLA

DCVax-L is on its way to approval for sure.